Aevi Genomic Medicine LLC

Aevi Genomic Medicine — Medgenics — Q3 2014 Earnings Presentation

42 slides from Aevi Genomic Medicine's earnings presentation, Oct 15, 2014

  1. Slide 1: Corporate Update October 15, 2014

    Corporate Update October 15, 2014

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results

  3. Slide 3: Agenda

    Agenda 3 • Q3 Financial Update • Operational Update – Phase 1/2 Trial in End Stage Renal Disease (ESRD) patients with Renal Anemia – Update on rare and orphan disease programs

  4. Slide 4: Company Overview

    Company Overview Corporate • NYSE - MKT: MDGN • 52 - week range: $4.75 - 9.00 • Approximate Market Cap: $ 9 0 Million (October 2014) • Headquarters: Wayne, PA • R&D: Misgav , Israel Technology • >$100 million invested since 2000 in an autologous protein production platform focused on ex vivo gene th

  5. Slide 5: Management Team - Proven Track Record

    Management Team - Proven Track Record • President, Shire Specialty Pharmaceuticals - Responsible for all aspects of the $2.5 billion business e.g., commercial, R&D, manufacturing, etc. • President, Life Sciences, Safeguard Scientifics – Lead Life Sciences PE team, responsible for both investment and

  6. Slide 6: Financial Update

    Financial Update ‘ medgenics

  7. Slide 7: Q3 2014 - Results of Operations

    Q3 2014 - Results of Operations 7 • Net R&D expenses for the 3 rd Quarter was $2.28 million decreased from $2.45 million for the same period in 2013 due to decrease in sub - contractor costs • G&A expenses for the 3 rd Quarter was $2.31 million decreasing from $2.56 million for the same period in 20

  8. Slide 8: Operational Update

    Operational Update ‘ medgenics

  9. Slide 9: Medgenics Vision

    Medgenics Vision 9 • Driven by our commitment to patients we strive to create the premier rare and orphan disease company by: – Having unparalleled understanding of the underlying science of rare diseases from pheno type to gen otype – Developing first - to - market or best - in - class therapies th

  10. Slide 10: Management Hypothesis

    Management Hypothesis • T echnology would be best suited for the treatment of rare and orphan diseases • Potentially highly disruptive to existing therapies • Platform could be substantially improved to increase production, durability , and secretion profile • Platform could be expanded beyond prote

  11. Slide 11: R&D Strategy

    R&D Strategy • Validated targets with clear proof of biological activity • Naturally occurring, autologous proteins and peptides • Well characterized safety and high specificity • Where continuous delivery is an advantage • Rare disease focused with high benefit/risk amenable to ex vivo gene therapy

  12. Slide 12: 2014 Strategic Objectives

    2014 Strategic Objectives 12 • Achieve clinical proof of concept using 2 nd Generation Platform producing autologous erythropoietin in ESRD patients – Improve secretion profile, durability >6 months – Phase 1/2 POC trial re - initiated in Israel, June 2014 • Initiate m ultiple protein/peptide progra

  13. Slide 13: Phase 1/2 trial in ESRD Patients with Renal Anemia

    Phase 1/2 trial in ESRD Patients with Renal Anemia 13

  14. Slide 14: TARGT (Transduced Autologous Restorative Gene Therapy)

    TARGT TM (Transduced Autologous Restorative Gene Therapy) 1. H arvest Micro - Organs from abdominal dermis using the proprietary DermaVac device. 2. Transduce fibroblasts in Micro - Organs via ex vivo gene therapy to create TARGT EPO 3. Wash out HDAd vector, measure production and choose TARGT EPO f

  15. Slide 15: Gen 1 System: eEPO Production Drops Off Rapidly

    0 5 10 15 20 25 30 -10 0 10 20 30 40 50 60 70 Serum e EPO , mU /ml Days from implantation Gen 1 System: eEPO Production Drops O ff Rapidly • Excellent safety and tolerability profile • One month of erythropoietin production translates into 4 - 5 months of anemia treatment given lifespan of red blood

  16. Slide 16: Significant Improvements to Technology Platform (Gen 2)

    Significant Improvements to Technology Platform (Gen 2) • Vector optimization • Linkers, promoters • Stabilizers • Codon optimization • Culture conditions • Defined media • Re - implantation technique • Device improvements – reduce shearing forces on the micro - organ • Engraftment • Use of Depo - M

  17. Slide 17: MDGN-201 Phase 1/2 Trial Design

    MDGN - 201 Trial Design 17 Prospective, Open - label , Dose Escalation study, to evaluate Safety and Efficacy (control of Hb 9 - 11 and < 12 g/ d L ) of TARGT EPO in ESRD patients . Study Summary Group Treatment N A Low dose eEPO 18 - 25 IU/kg/day 3 + 3 * B Mid dose eEPO 35 - 45 IU/kg/day 3 + 3 * C

  18. Slide 18: TARGT EPO Product Profile: Efficacy

    TARGT EPO Product Profile EFFICACY • Long acting duration of effect – Physiologic levels of eEPO for >6 months and preferably 1 year • Autologous – Production of a ll 14 isoforms of eEPO vs one for rHuEPO , mimicking the natural system. This may improve receptor binding and enhance cardio - renal pr

  19. Slide 19: TARGT EPO Product Profile: Safety and Administration

    TARGT EPO Product Profile SAFETY • Elimination of s upratherapeutic p eaks – High C max has been associated with hypertension and serious thromboembolic events * • Reduction in blood pressure vs. injectable rHuEPO ADMINISTRATION • Simple outpatient procedure • Increase compliance due to implantation

  20. Slide 20: Initial Clinical Data & Observations

    Initial Clinical Data & Observations Three patients treated to date are (3.5), (2.5), and (1) month(s) post - implantation of TARGT EPO • Pharmacokinetics – Duration: P atients are meeting target secretion profile of continuously producing physiologic levels of endogenous EPO sufficient to maintain

  21. Slide 21: Patient One Run-in Period

    21 Patient One Run - in Period Supratherapeutic doses of rHuEPO required to maintain hemoglobin levels Patient Description: Age: 70 Sex: Male Dialysis: 4 years Underlying disease: HTN & T2DM Days Pre-implantation -25 -20 -15 -10 -5 0 Serum Hb, g/dL 8 9 10 11 12 13 Days Pre-implantation -25 -20 -15 -

  22. Slide 22: Patient One Interim Results

    22 Patient One Interim Results Patient Description: Age: 70 Sex: Male Dialysis: 4 years Underlying disease: HTN & T 2 DM • 3 Transduced Micro - Organs (TARG T EPO ) implanted • Patient stabilizes after approximately 30 days • Target Hb is reached with approx 100x lower C MAX than rHuEPO • Patient ap

  23. Slide 23: Patient One – Actively Regulated Reticulocytosis

    23 Patient One – Actively Regulated Reticulocytosis Days from implantation 0 20 40 60 80 100 120 Reticulocytes (10 9 /L) 30 40 50 60 70 80 90 100 ( 3 ) TARGT EPO implanted • O ngoing reticulocytosis is evidence of response to eEPO • Repeated peaks and troughs may be indicative of autoregulation • *P

  24. Slide 24: Patient Two Interim Results

    24 Patient Two Interim Results Patient Description: Age: 26 Sex: Male Dialysis: 10 months Underlying disease: IgA Neph . • 2 Transduced Micro Organs (TARGT EPO ) implanted • Patient displays higher peak eEPO but stabilizes after 45 days • Target Hb is reached with approx 100 x lower C MAX than rHuEP

  25. Slide 25: Patient Three Interim Results

    Patient Three Interim Results Patient Description: Age: 74 Sex: Female Dialysis: 1.4 years Underlying disease: HTN & T2DM One months post implantation renal anemia is well controlled Target Hb 9 - 11, <12g/ dL Days from implantation 0 10 20 30 40 Serum Hb, g/dL 8 9 10 11 12 13 Days from implantation

  26. Slide 26: Initial Observations and Next Steps

    Initial Observations and Next steps • It has been well tolerated and very effective in controlling renal anemia in ESRD patients thus far. • TARGT EPO , in conjunction with the patient’s residual capacity to produce eEPO and regulate Hb , appears to mimic the restoration of the natural erythropoieti

  27. Slide 27: TARGT EPO in ESRD Patients Hypo-Responsive to rHuEPO

    TARGT EPO in ESRD Patients Hypo - Responsive to rHuEPO 27

  28. Slide 28: US Market for rHuEPO

    US Market for rHuEPO 28 Source: Evaluate Pharma ®; • Steady decline in rHuEPO usage due to significant safety concerns related to: – Increased risk of thromboembolic events (CHOIR, TREAT) – Increased cancer risk – Supratherapeutic doses have been implicated in these safety issues • Inclusion of inje

  29. Slide 29: Bulk of Diagnosed CKD Patients in Stage III-V

    Bulk of Diagnosed CKD Patients in Stage III - V (ESRD) - 2.0 4.0 6.0 8.0 10.0 12.0 14.0 I II III IV V- ESRD Patients MM Stage US CKD Population 29 - 400 800 1,200 1,600 I II III IV V - ESRD Patients 000’s Stage Diagnosed Population • The US CKD patient population is approximately 26 million • The ma

  30. Slide 30: Hypo-Responsive Patient Flow

    Hypo - Responsive Patient Flow 30 600K ESRD Patients ~ 40 - 70 K Hypo - Responsive ESRD patients ~ 366K ESRD patients on ESA • Estimated cost of at least $30K/year for anemia management • > $20K/year rHuEPO • $5 - 10K/year in transfusion costs Source: USRDS database and primary company research Pote

  31. Slide 31: TARGT EPO in Hypo-Responsive ESRD Patients

    TARGT EPO in Hypo - Responsive ESRD Patients 31 Rationale: • Continuous physiologic levels of eEPO will stimulate bone marrow more effectively and safely than intermittent IV dosing • Potential orphan designation • Reduction of overall patient costs ( rHuEPO , iron management and transfusion) • Rapi

  32. Slide 32: TARGT EPO in Beta Thalassemia

    TARGT EPO in Beta Thalassemia 32

  33. Slide 33: Beta Thalassemia

    Beta Thalassemia 33 • Beta Thalassemia is the most common genetic disease in the world whose characteristics in symptomatic patients include 1 : • Orphan population with significant unmet need • Severe anemia, iron overload, and splenomegaly • Patients generally require transfusions and/or bone marr

  34. Slide 34: Beta Thalassemia Patient Flow

    Beta Thalassemia Patient Flow 34 ~100,000 Symptomatic Beta Thalassemia patients W.W. ~ 50 , 000 Beta Thalassemia Intermedia patients W.W. ~ 15 , 500 Beta Thalassemia Intermedia Patients US/EU • Avg. cost of ~$100K/year* • ~$60K/year in transfusion costs • (>12 units of blood per year) • ~$40K/year i

  35. Slide 35: TARGT EPO in Beta Thalassemia

    TARGT EPO in Beta Thalassemia 35 • Rationale: • eEPO levels are lower than expected in Beta Thalassemia patients • rHuEPO has shown the ability to reduce transfusions and increase hemoglobin levels in Beta Thalassemia patients 1 • Safety concerns have limited usage of rHuEPO • Continuous physiologic

  36. Slide 36: TARGT EPO - Additional Indications of Interest

    TARGT EPO - Additional Indications of Interest P latform has the potential to be applied across numerous indications • Anemic CKD transplant candidates – Reducing transfusions would prevent increased immunogenicity, shortening “wait - times” and improving transplant outcomes • Peritoneal Dialysis (P

  37. Slide 37: TARGT GLP-2 in Short Bowel Syndrome

    TARGT GLP - 2 ™ in Short Bowel Syndrome 37

  38. Slide 38: Glucagon-like peptide (GLP-2)

    Glucagon - like peptide 2 (GLP - 2) • 33 amino acid naturally occurring peptide, t 1 / 2 = 6 - 7 min. • Produced by L cells of small intestine • Several important functions: – Increases intestinal absorption – Stimulates intestinal growth – Reduces bone breakdown • Improves intestinal absorption in

  39. Slide 39: MDGN GLP-2 Program

    MDGN GLP - 2 Program • We adapted the TARGT platform for expression of peptides < 40 amino acids including GLP - 2 • Program has advanced to in vivo stage in SCID mice (n= 5 ) 39 0 5 10 15 20 25 30 7 18 27 39 49 60 Serum GLP - 2 ng/ml Days from Implantation

  40. Slide 40: MDGN TARGT GLP-2 vs teduglutide

    • TARGT GLP - 2 should provide a more favorable PK profile – physiologic levels of continuous GLP - 2 – lower peak dose and continuous coverage • Indications include short bowel syndrome and IBD • We plan to approach regulatory authorities in H 1 2015 MDGN TARGT GLP - 2 vs teduglutide 40 Source NPS

  41. Slide 41: Conclusions

    Conclusions • The second generation platform is working well, as evidenced by the positive initial data we are seeing in our ongoing clinical trial • We have identified multiple commercially attractive orphan indications for TARGT EPO where rapid proof - of - concept can be achieved • We have expand

  42. Slide 42: Upcoming Activities Include…

    Upcoming Activities Include… 42 TIMING Present at European Society of Gene and Cell Therapy (ESGCT) Oct 14 Complete enrollment in MDGN - 201 study Q4 14 Initiate Phase 2 study in Hypo - Responsive Patients Q1 15 Initiate Phase 2 study in Beta Thalassemia Patients H1 15 Approach regulatory authoritie

Medgenics — Q3 2014 Earnings Presentation on 6ix